{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:12:05Z","timestamp":1790953925175,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011034","name":"Instituto Espa\u00f1ol de Oceanograf\u00eda","doi-asserted-by":"publisher","award":["2022PJKF88"],"award-info":[{"award-number":["2022PJKF88"]}],"id":[{"id":"10.13039\/501100011034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005389","name":"Universit\u00e0 degli Studi dell'Insubria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018429","name":"European Institute of Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021016","name":"Istituto di Ricovero e Cura a Carattere Scientifico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semcancer.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:18:47Z","timestamp":1753139927000},"page":"40-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives"],"prefix":"10.1016","volume":"115","author":[{"given":"Adriana","family":"Albini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Cantelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mortara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.07.008_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.14694\/EdBook_AM.2015.35.57","article-title":"Early detection of cancer: past, present, and future","author":"Schiffman","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.semcancer.2025.07.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-42542-9_1","article-title":"Obesity and risk of cancer: an introductory overview","volume":"208","author":"Pischon","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.semcancer.2025.07.008_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/MOU.0000000000001041","article-title":"Metabolic syndrome, obesity and cancer risk","volume":"32","author":"Belladelli","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.semcancer.2025.07.008_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1385479","article-title":"Inflammation and cancer: friend or foe?","volume":"15","author":"Turizo-Smith","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.semcancer.2025.07.008_bib6","series-title":"Endotext [Internet]","article-title":"Social and Environmental Factors Influencing Obesity","author":"Lee","year":"2019"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.metabol.2012.01.021","article-title":"A cross-over study of the acute effects of espresso coffee on glucose tolerance and insulin sensitivity in people with type 2 diabetes mellitus","volume":"61","author":"Krebs","year":"2012","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/ar3900","article-title":"Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis","volume":"14","author":"Stavropoulos-Kalinoglou","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-024-00204-z","article-title":"S. Repurposing metabolic regulators: antidiabetic drugs as anticancer agents","volume":"5","author":"Dhas","year":"2024","journal-title":"Mol. Biomed."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib10","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.3390\/ijms25074083","article-title":"Metformin: a dual-role player in cancer treatment and prevention","volume":"25","author":"Galal","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.07.008_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms22041680","article-title":"Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors","volume":"22","author":"D\u0105browski","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/dom.14454","article-title":"Association of obesity with postacute sequelae of COVID-19","volume":"23","author":"Aminian","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4093\/dmj.2021.0077","article-title":"Obesity, diabetes, and increased cancer progression","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.semcancer.2025.07.008_bib16","series-title":"StatPearls [Internet]","article-title":"Type 2 diabetes. [updated 2023 Jun 23]","author":"Goyal","year":"2025"},{"key":"10.1016\/j.semcancer.2025.07.008_bib17","unstructured":"\u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\u3009."},{"key":"10.1016\/j.semcancer.2025.07.008_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib19","article-title":"Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions","volume":"67","author":"de Andrade Mesquita","year":"2023","journal-title":"Arch. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamaoncol.2018.5327","article-title":"Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study","volume":"5","author":"Iyengar","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/EJE-21-0669","article-title":"Metabolic health during a randomized controlled lifestyle intervention in women with PCOS","volume":"186","author":"Dietz de Loos","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"31","key":"10.1016\/j.semcancer.2025.07.008_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2014.58.9952","article-title":"Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study","volume":"33","author":"Movahedi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPA.0000000000000974","article-title":"Obesity and pancreatic cancer: overview of epidemiology and potential prevention by weight loss","volume":"47","author":"Xu","year":"2018","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3350\/cmh.2020.0176","article-title":"Obesity and the risk of primary liver cancer: A systematic review and meta-analysis","volume":"27","author":"Sohn","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib25","first-page":"88","article-title":"Global patterns in excess body weight and the associated cancer burden","volume":"69","author":"Sung","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2025.07.008_bib26","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04205","article-title":"Global obesity epidemic and rising incidence of early-onset cancers","volume":"14","author":"Chen","year":"2024","journal-title":"J. Glob. Health"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib28","first-page":"1529","article-title":"Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients","volume":"24","author":"Tessitore","year":"2004","journal-title":"Int. J. Oncol."},{"issue":"20","key":"10.1016\/j.semcancer.2025.07.008_bib29","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1111\/j.1742-4658.2009.07303.x","article-title":"Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue","volume":"276","author":"Rutkowski","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.semcancer.2025.07.008_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2016.06.028","article-title":"Adiponectin, TNF-\u03b1 and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"86","author":"Liu","year":"2016","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.008_bib31","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.3390\/cancers12123798","article-title":"Obesity and cancer metastasis: molecular and translational perspectives","volume":"12","author":"Annett","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib32","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10043","article-title":"The role of insulin and insulin-like growth factors in the increased risk of cancer in diabetes","volume":"2","author":"Leroith","year":"2011","journal-title":"Rambam Maimonides Med. J."},{"issue":"15","key":"10.1016\/j.semcancer.2025.07.008_bib33","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.3390\/ijms22157797","article-title":"Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer","volume":"22","author":"Janssen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.07.008_bib34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","article-title":"Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism","volume":"12","author":"Kalyanaraman","year":"2017","journal-title":"Redox Biol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib35","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1096\/fj.03-1101fje","article-title":"Angiogenesis in an in vivo model of adipose tissue development","volume":"18","author":"Neels","year":"2004","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/0008-5472.CAN-23-1641","article-title":"FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CEJ.0000000000000898","article-title":"Physical activity and exercise health benefits: cancer prevention, interception, and survival","volume":"34","author":"Albini","year":"2025","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2025.07.008_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.629666","article-title":"Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis","volume":"11","author":"Dong","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10549-018-5051-0","article-title":"Clinical implication of E-cadherin deficiency in lobular breast cancer","volume":"173","author":"Corso","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12916-022-02702-9","article-title":"Separating the effects of early and later life adiposity on colorectal cancer risk: a Mendelian randomization study","volume":"21","author":"Papadimitriou","year":"2023","journal-title":"BMC Med."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib42","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/biomedicines11051290","article-title":"The role of adipokines in health and disease","volume":"11","author":"Clemente-Su\u00e1rez","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib43","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3390\/cancers15030814","article-title":"Metabolic health, mitochondrial fitness, physical activity, and cancer","volume":"15","author":"Clemente-Su\u00e1rez","year":"2023","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.semcancer.2025.07.008_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e35200","article-title":"Dissecting the emerging role of cancer-associated adipocyte-derived cytokines in remodeling breast cancer progression","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cpt.2023.11.001","article-title":"Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer","volume":"2","author":"Sarangi","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.semcancer.2025.07.008_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.semcancer.2025.05.013","article-title":"The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: insights for future research","volume":"113","author":"Kounatidis","year":"2025","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87489","article-title":"Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells","volume":"2","author":"Wang","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41523-021-00324-7","article-title":"Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer","volume":"7","author":"Gyamfi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s43856-024-00589-6","article-title":"Converging deep learning and human-observed tumor-adipocyte interaction as a biomarker in colorectal cancer","volume":"4","author":"Reitsam","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.semcancer.2025.07.008_bib51","doi-asserted-by":"crossref","unstructured":"Sumiya Dalangood, Cegui Hu, Chenwei Yuan, Xiang Li, Wen Qiao, Hanjun Li, Rongyu Zhang, Luying Li, Peng Li, Xiang Yu, Wenjin Yin, Jinsong Lu, Jun Gui, Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. \u3008https:\/\/doi.org\/10.1101\/2024.10.18.618991\u3009.","DOI":"10.1101\/2024.10.18.618991"},{"key":"10.1016\/j.semcancer.2025.07.008_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1408844","article-title":"Exploring the multifaceted role of obesity in breast cancer progression","volume":"12","author":"Kakkat","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.008_bib53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41419-023-06230-z","article-title":"Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy","volume":"14","author":"Huang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24412","article-title":"The mir-199b-5p encapsulated in adipocyte-derived exosomes mediates radioresistance of colorectal cancer cells by targeting JAG1","volume":"10","author":"Lv","year":"2024","journal-title":"Heliyon"},{"issue":"13","key":"10.1016\/j.semcancer.2025.07.008_bib55","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/nu16132098","article-title":"A mediation analysis of obesity and adiponectin association with postmenopausal breast cancer risk: a nested cohort study in the international breast cancer intervention study II (IBIS-II) prevention trial","volume":"16","author":"Macis","year":"2024","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.008_bib56","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1078-0432.CCR-08-2649","article-title":"Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo","volume":"15","author":"Landskroner-Eiger","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm.2277","article-title":"Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin","volume":"17","author":"Holland","year":"2011","journal-title":"Nat. Med."},{"issue":"35","key":"10.1016\/j.semcancer.2025.07.008_bib58","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: evidence, challenges, and opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib59","article-title":"Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer","volume":"5","author":"Brown","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1940-6207.CAPR-18-0262","article-title":"A phase IIa trial of metformin for colorectal cancer risk reduction among individuals with history of colorectal adenomas and elevated body mass index","volume":"13","author":"Zell","year":"2020","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib61","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/biology13050302","article-title":"Metformin: from diabetes to cancer-unveiling molecular mechanisms and therapeutic strategies","volume":"13","author":"Amengual-Cladera","year":"2024","journal-title":"Biology"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib62","first-page":"59","article-title":"Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers","volume":"2","author":"Bao","year":"2014","journal-title":"Ann. Transl. Med."},{"issue":"35","key":"10.1016\/j.semcancer.2025.07.008_bib63","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.23.00296","article-title":"Effect of metformin versus placebo on new primary cancers in canadian cancer trials group MA.32: a secondary analysis of a phase iii randomized double-blind trial in early breast cancer","volume":"41","author":"Goodwin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.07.008_bib64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-12-118","article-title":"Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial","volume":"12","author":"Higurashi","year":"2012","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib65","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cancers16071325","article-title":"Role of SGLT2 inhibitors, DPP-4 inhibitors, and metformin in pancreatic cancer prevention","volume":"16","author":"Laeeq","year":"2024","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib66","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib68","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10911-019-09429-z","article-title":"Metformin and breast cancer: molecular targets","volume":"24","author":"Faria","year":"2019","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib70","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s12967-022-03809-6","article-title":"Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials","volume":"20","author":"Bellerba","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00280-025-04791-8","article-title":"Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial","volume":"95","author":"Salah","year":"2025","journal-title":"Cancer Chemother. Pharm."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib72","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/pharmaceutics17050558","article-title":"Metformin-based combination approaches for triple-negative breast cancer","volume":"17","author":"Sirhan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.008_bib73","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djae070","article-title":"Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study","volume":"116","author":"van Eijck","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.008_bib74","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0053","article-title":"Anticancer activity of metformin: a systematic review of the literature","volume":"5","author":"Aljofan","year":"2019","journal-title":"Future Sci. OA"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/0008-5472.CAN-23-3932","article-title":"Exploring the role of hyperinsulinemia in obesity-associated tumor development","volume":"84","author":"V\u00e9lez-Bonet","year":"2024","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.008_bib76","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","article-title":"Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies","volume":"94","author":"Appleby","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"13","key":"10.1016\/j.semcancer.2025.07.008_bib77","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4161\/cc.8.13.8985","article-title":"Chronic inflammation, the tumor microenvironment and carcinogenesis","volume":"8","author":"Gonda","year":"2009","journal-title":"Cell Cycle"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.86","article-title":"Metformin inhibits melanoma development through autophagy and apoptosis mechanisms","volume":"2","author":"Tomic","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.07.008_bib79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/ncomms1859","article-title":"Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC","volume":"3","author":"Blandino","year":"2012","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib80","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3892\/ijo.2013.2077","article-title":"Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway","volume":"43","author":"Yi","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2025.07.008_bib81","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib82","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/carcin\/bgu001","article-title":"Paradoxic effects of metformin on endothelial cells and angiogenesis","volume":"35","author":"Dallaglio","year":"2014","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112659","article-title":"Metformin attenuates expression of angiogenic and inflammatory genes in human endometriotic stromal cells","volume":"404","author":"Yari","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193031","article-title":"Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo","volume":"13","author":"Han","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.008_bib85","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11684-015-0384-0","article-title":"Metformin and metabolic diseases: a focus on hepatic aspects","volume":"9","author":"Zheng","year":"2015","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.008_bib87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4239\/wjd.v14.i5.585","article-title":"Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes","volume":"14","author":"Sayedali","year":"2023","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.semcancer.2025.07.008_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.975912","article-title":"Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials","volume":"13","author":"Nabrdalik","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70490","article-title":"Association between GLP1 RAS use and risk of colorectal cancer: a systematic review and meta-analysis)","volume":"8","author":"Bushi","year":"2025","journal-title":"Health Sci. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2025.07.008_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107719","article-title":"Metabolic imbalance and brain tumors: the interlinking metabolic pathways and therapeutic actions of antidiabetic drugs","volume":"215","author":"Kim","year":"2025","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib92","doi-asserted-by":"crossref","first-page":"946","DOI":"10.62347\/OLUR1927","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib93","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdi.12466","article-title":"Is GLP-1 a hormone: whether and when?","volume":"7 1","author":"D'Alessio","year":"2016","journal-title":"J. Diabetes Invest."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib95","doi-asserted-by":"crossref","first-page":"E534","DOI":"10.1002\/ijc.29193","article-title":"The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells","volume":"136","author":"Orecchioni","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib96","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrclinonc.2012.120","article-title":"Cancer prevention by targeting angiogenesis","volume":"9","author":"Albini","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib98","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/biom14111479","article-title":"Anti-diabetic therapies and cancer: from bench to bedside","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"issue":"17","key":"10.1016\/j.semcancer.2025.07.008_bib99","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1158\/1078-0432.CCR-16-0695","article-title":"Cancer prevention and interception: a new era for chemopreventive approaches","volume":"22","author":"Albini","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.07.008_bib100","article-title":"Anti-inflammatory benefits of semaglutide: State of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.semcancer.2025.07.008_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/srep18673","article-title":"Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells","volume":"6","author":"Talarico","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: A systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib103","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib104","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib105","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd","year":"2015","journal-title":"Endocrinology"},{"issue":"792","key":"10.1016\/j.semcancer.2025.07.008_bib106","first-page":"1539","article-title":"Focus sur le tirz\u00e9patide, un double agoniste unimol\u00e9culaire GIP-GLP-1 dans le diab\u00e8te de type 2 [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes]","volume":"18","author":"Scheen","year":"2022","journal-title":"Rev. Med. Suisse"},{"key":"10.1016\/j.semcancer.2025.07.008_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111758","article-title":"Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"213","author":"Popovic","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/0113892037287976231212104607","article-title":"An update on dipeptidyl peptidase-IV inhibiting peptides","volume":"25","author":"Sivaraman","year":"2024","journal-title":"Curr. Protein Pept. Sci."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.008_bib109","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/cancers13092191","article-title":"CD26\/DPP-4: type 2 diabetes drug target with potential influence on cancer biology","volume":"13","author":"Kawakita","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40261-021-01088-5","article-title":"First-in-human, single-ascending dose and food effect studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of cetagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus","volume":"41","author":"Wang","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib111","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1111\/bcp.15209","article-title":"A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin","volume":"88","author":"Lu","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.semcancer.2025.07.008_bib112","article-title":"Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003550","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study","volume":"11","author":"Pradhan","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib114","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.semcancer.2025.07.008_bib115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fonc.2020.00405","article-title":"Impact of DPP4 inhibitors in survival of patients with prostate, pancreas, and breast cancer","volume":"10","author":"Shah","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib116","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1007\/s12094-023-03187-5","article-title":"Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer","volume":"25","author":"Zuo","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib117","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s40001-024-01955-9","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus","volume":"29","author":"Zhao","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.semcancer.2025.07.008_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.731453","article-title":"The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.metabol.2015.10.002","article-title":"Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate","volume":"65","author":"Lee","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.semcancer.2025.07.008_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","article-title":"CD26\/DPP4 \u2013 a potential biomarker and target for cancer therapy","volume":"198","author":"Enz","year":"2019","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","article-title":"Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib122","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.semcancer.2025.07.008_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.semcancer.2025.07.008_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib125","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/0929867324666170920144130","article-title":"Nutraceuticals and \"repurposed\" drugs of phytochemical origin in prevention and interception of chronic degenerative diseases and cancer","volume":"26","author":"Albini","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.semcancer.2025.07.008_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res Clin. Pract."},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.008_bib127","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.semcancer.2025.07.008_bib128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.diabres.2018.01.026","article-title":"What the oncologist can learn from diabetes studies: epidemiology, prevention, management, cure","volume":"143","author":"Albini","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","article-title":"Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study","volume":"8","author":"Kohsaka","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"23","key":"10.1016\/j.semcancer.2025.07.008_bib130","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib131","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/dom.14018","article-title":"A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes","volume":"22","author":"Mulder","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"17","key":"10.1016\/j.semcancer.2025.07.008_bib132","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.3390\/ijerph20176671","article-title":"Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging","volume":"20","author":"Sch\u00f6nberger","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.semcancer.2025.07.008_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176803","article-title":"Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies","volume":"978","author":"Naeimzadeh","year":"2024","journal-title":"Eur. J. Pharm."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib134","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/biomedicines11071867","article-title":"SGLT2 inhibitors as potential anticancer agents","volume":"11","author":"Basak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.semcancer.2025.07.008_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib136","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40170-023-00306-2","article-title":"Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study","volume":"11","author":"Park","year":"2023","journal-title":"Cancer Metab."},{"key":"10.1016\/j.semcancer.2025.07.008_bib137","article-title":"Sulfonylurea and cancer risk among patients with type 2 diabetes: a population-based cohort study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"46","key":"10.1016\/j.semcancer.2025.07.008_bib138","doi-asserted-by":"crossref","first-page":"81027","DOI":"10.18632\/oncotarget.17515","article-title":"Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.07.008_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154780","article-title":"Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis","volume":"120","author":"Arvind","year":"2021","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.008_bib140","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1634\/theoncologist.2013-0177","article-title":"Effects of sulfonylureas on tumor growth: a review of the literature","volume":"18","author":"Pasello","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib141","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12876-024-03477-4","article-title":"Effect of diabetes mellitus type 2 and sulfonylurea on colorectal cancer development: a case-control study","volume":"24","author":"Rezazadeh","year":"2024","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib142","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ajg.2013.7","article-title":"Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"18","key":"10.1016\/j.semcancer.2025.07.008_bib143","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/14656566.2019.1672660","article-title":"Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2019","journal-title":"Expert Opin. Pharm."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib144","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/15733998113099990065","article-title":"Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug","volume":"9","author":"Karak","year":"2013","journal-title":"Curr. Diabetes Rev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib146","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/1874467211205020272","article-title":"Peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) agonists on glycemic control, lipid profile and cardiovascular risk","volume":"5","author":"Derosa","year":"2012","journal-title":"Curr. Mol. Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib147","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc11-2197","article-title":"Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study","volume":"36","author":"Chen","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib148","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","article-title":"Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis","volume":"18","author":"Bosetti","year":"2013","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib149","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib150","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/nu16111749","article-title":"Combined effects of physical activity and diet on cancer patients: a systematic review and meta-analysis","volume":"16","author":"Dinas","year":"2024","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib151","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11764-020-00864-0","article-title":"Effects of dietary and physical activity interventions on generic and cancer-specific health-related quality of life, anxiety, and depression in colorectal cancer survivors: a randomized controlled trial","volume":"14","author":"Ho","year":"2020","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.semcancer.2025.07.008_bib152","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1741-7015-10-138","article-title":"Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis","volume":"10","author":"Yamaoka","year":"2012","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib153","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/nu16060756","article-title":"Effect of aromatic herbs and spices present in the mediterranean diet on the glycemic profile in type 2 diabetes subjects: a systematic review and meta-analysis","volume":"16","author":"Garza","year":"2024","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.008_bib154","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.clnu.2022.10.001","article-title":"Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: a systematic review and meta-analysis","volume":"41","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2022","journal-title":"Clin. Nutr."},{"issue":"18","key":"10.1016\/j.semcancer.2025.07.008_bib155","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/nu16183068","article-title":"Effect of a phytochemical-rich olive-derived extract on anthropometric, hematological, and metabolic parameters","volume":"16","author":"Aiello","year":"2024","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.008_bib156","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/CEJ.0000000000000782","article-title":"Cancer prevention: innovative strategies in the role of the European Cancer Prevention Organization","volume":"32","author":"Corso","year":"2023","journal-title":"Eur. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib157","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/antiox12020297","article-title":"Exercise restores hypothalamic health in obesity by reshaping the inflammatory network","volume":"12","author":"Della Guardia","year":"2023","journal-title":"Antioxidants"},{"issue":"24","key":"10.1016\/j.semcancer.2025.07.008_bib158","doi-asserted-by":"crossref","first-page":"13258","DOI":"10.3390\/ijerph182413258","article-title":"The role of exercise training on low-grade systemic inflammation in adults with overweight and obesity: a systematic review","volume":"18","author":"Gonzalo-Encabo","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.008_bib159","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1210\/jc.2004-1011","article-title":"Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects","volume":"90","author":"O'Brien","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib160","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/sj.ijo.0802987","article-title":"Angiogenic factors are elevated in overweight and obese individuals","volume":"29","author":"Silha","year":"2005","journal-title":"Int. J. Obes."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.008_bib161","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/1120009X.2020.1777722","article-title":"Negative impact of high body mass index on cetuximab-mediated cellular cytotoxicity against human colon carcinoma cells","volume":"33","author":"Campiotti","year":"2021","journal-title":"J. Chemother."},{"key":"10.1016\/j.semcancer.2025.07.008_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2024.1530811","article-title":"GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks","volume":"5","author":"Ilias","year":"2025","journal-title":"Front. Clin. Diabetes Health"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.008_bib163","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.008_bib164","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-023-07241-2","article-title":"Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials","volume":"205","author":"Johansson","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.008_bib165","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1055-9965.EPI-24-1644","article-title":"Plasma insulin-like growth factor-binding protein-7 is positively associated with age, obesity, mortality, and cancer in postmenopausal women","volume":"34","author":"Orenduff","year":"2025","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.008_bib166","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.trecan.2025.04.010","article-title":"Repurposing glucose-lowering drugs for cancer therapy","volume":"11","author":"Luconi","year":"2025","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.008_bib167","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/ijms26104780","article-title":"SGLT2 inhibitors in cancer patients: a comprehensive review of clinical, biochemical, and therapeutic implications in cardio-oncology","volume":"26","author":"Greco","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.008_bib168","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1940-6207.CAPR-22-0310","article-title":"Cancer prevention prioritized at AACR annual meeting and a new working group","volume":"15","author":"Albini","year":"2022","journal-title":"Cancer Prev. Res. (Phila)"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:49:11Z","timestamp":1772880551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":168,"alternative-id":["S1044579X25001026"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.07.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}